MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

9.555 -0.395 (-3.97%)

Streaming Delayed Price Updated: 2:03 PM EDT, May 15, 2026 Add to My Watchlist

Price and Volume

Volume	342,265
Open	9.880
Bid (Size)	9.540 (1,000)
Ask (Size)	9.570 (300)
Prev. Close	9.950
Today's Range	9.450 - 9.940
52wk Range	4.550 - 11.85
Shares Outstanding	80,479,684
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

May 14, 2026

From MeiraGTx

Via GlobeNewswire

Performance

YTD	+22.3%	+22.3%
1 Month	-15.4%	-15.4%
3 Month	+29.8%	+29.8%
6 Month	+15.7%	+15.7%
1 Year	+106.1%	+106.1%

More News

MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen ↗

May 14, 2026

Via Chartmill

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

April 16, 2026

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

April 16, 2026

From MeiraGTx

Via GlobeNewswire

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? ↗

November 10, 2025

Via Stocktwits

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

April 16, 2026

From MeiraGTx

Via GlobeNewswire

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

April 14, 2026

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

March 26, 2026

From MeiraGTx

Via GlobeNewswire

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

Via Investor Brand Network

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?

December 18, 2025

Via MarketMinute

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

November 13, 2025

From MeiraGTx

Via GlobeNewswire

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration ↗

November 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

November 10, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

October 07, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Sales Jump 1,133 Percent ↗

August 14, 2025

Via The Motley Fool

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

August 14, 2025

From MeiraGTx

Via GlobeNewswire

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 09, 2025

From MeiraGTx

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

March 13, 2025

Via Chartmill

Frequently Asked Questions

Is MeiraGTx Holdings plc - Ordinary Shares publicly traded?

Yes, MeiraGTx Holdings plc - Ordinary Shares is publicly traded.

What exchange does MeiraGTx Holdings plc - Ordinary Shares trade on?

MeiraGTx Holdings plc - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for MeiraGTx Holdings plc - Ordinary Shares?

The ticker symbol for MeiraGTx Holdings plc - Ordinary Shares is MGTX on the Nasdaq Stock Market

What is the current price of MeiraGTx Holdings plc - Ordinary Shares?

The current price of MeiraGTx Holdings plc - Ordinary Shares is 9.555

When was MeiraGTx Holdings plc - Ordinary Shares last traded?

The last trade of MeiraGTx Holdings plc - Ordinary Shares was at 05/15/26 02:03 PM ET

What is the market capitalization of MeiraGTx Holdings plc - Ordinary Shares?

The market capitalization of MeiraGTx Holdings plc - Ordinary Shares is 768.98M

How many shares of MeiraGTx Holdings plc - Ordinary Shares are outstanding?

MeiraGTx Holdings plc - Ordinary Shares has 769M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.